Dimethyl fumarate (Tecfidera®)

Assessment Status NCPE Assessment Process Complete
Drug Dimethyl fumarate
Brand Tecfidera®
Indication For the treatment of adult patients with relapsing remitting multiple sclerosis (MS)
Assessment Process
Rapid review commissioned 04/02/2014
Rapid review completed 06/03/2014
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 16/07/2014
NCPE assessment completed 14/01/2015
NCPE assessment outcome Reimbursement not recommended

Technical Summary


Following pricing negotiation, the HSE has approved reimbursement of Tecfidera® under the High Tech Drugs Scheme.